ERECTILE DYSFUNCTION
The long-term use of sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis) inerectile dysfunction has not been well studied. The drugs can increase the likelihood of satisfying sex, but about 2 out of every 10 users will experience adverse effects.
To systematically review the evidence on efficacy and harms of pharmaceutical treatments used in the management of male erectile dysfunction (ED); to explore the clinical utility of routine hormonal blood tests (e.g. testosterone, prolactin) for identifying and treating hormonal disorders and thereby affecting therapeutic outcomes for ED.
Authors conducted a meta‐analysis to evaluate the effectiveness of psychological interventions for the treatment of erectile dysfunction (ED) compared to oral drugs, local injection, vacuum devices, or other psychological interventions. Distinct sources of randomised clinical trials (RCTs) were searched, such as electronic databases (between 1966 and 2007). We also crosschecked references and contacted scientific societies. Eleven trials involving 398 men met the inclusion criteria. Conclusions: there is evidence that group therapy (GT) improves ED in selected patients. Focused sex GT showed greater efficacy than control group. Men who received GT plus sildenafil showed significant improvement of ED and were less likely than those receiving only sildenafil to drop out. In comparing the effectiveness of psychological interventions for the treatment of ED versus local injection and vacuum devices, no difference was found.
Men who experience erectile dysfunction (ED) are unable to achieve an erection sufficient for satisfactory sexual intercourse. One of the most common treatment is with prostaglandin E1 (PGE1), a naturally occurring PGE used to treat this dysfunction. Men either inject PGE1 into their penis or insert a pellet containing the drug into the end of the penis (into the urethra). The review of trials found that men using PGE1 reported more satisfactory sexual experiences. Higher doses gave greater benefits but also increased the adverse effects. The most common adverse effect is some pain, and men may prefer the urethral medication rather than injections.
Erectile dysfunction is a common multi‐factorial complication of diabetes mellitus. Newer medications, like the so‐called PDE‐5 inhibitors result in enhancement of penile erection. The introduction of sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis), have altered the management of erectile dysfunction. In this review we assessed the effect of these agents on erectile dysfunction in diabetic people. Eight studies with 976 men randomised to PDE‐5 inhibitor therapy and a duration of mainly 12 weeks were evaluated. Compared to placebo treatment, these agents showed favourable effects in scores estimating sexual life, with an increased rate of adverse effects like headache and flushing after PDE‐inhibitor therapy. Mortality was not reported in any of the included trials. Quality of life, with the exception of scores for sexual life, was not relevantly affected. If taken as prescribed, PDE‐5 inhibitors comprise a valuable treatment option for erectile dysfunction in men with diabetes.
Bibliographic details: Tsertsvadze A, Yazdi F, Fink H A, MacDonald R, Wilt T J, Soares-Weiser K, Bella A J, Deforge D, Garritty C, Ansari M, Sampson M, Daniel R, Moher D . Diagnosis and treatment of erectile dysfunction. Rockville, MD, USA: Agency for Healthcare Research and Quality. Evidence Report/Technology
OBJECTIVE: To assess erectile dysfunction in patients with prostate cancer undergoing surgery by radical prostatectomy, laparoscopic prostatectomy or robotic prostatectomy
The effect of lifestyle modification and cardiovascular risk factor reduction onerectile dysfunction
This review concluded that the evidence that lifestyle modification and pharmacotherapy for cardiovascular risk factors were effective in improving sexual function in men with erectile dysfunction was strengthened. Despite the limitations of the evidence available, this was a generally well-conducted review and the conclusions are likely to be reliable.
This review concluded that evidence was insufficient to suggest that acupuncture was an effective intervention for treating erectile dysfunction. In light of the small sample size and generally poor quality of included studies, the authors' cautious conclusions are likely to be reliable.
This generally well-conducted review concluded that oral PDE-5 inhibitors improved erectile function and had similar efficacy and safety profiles; the efficacy and value of hormone treatments remained uncertain. Despite some limitations, the review included a large number of studies and the direction of effect seemed to be consistent across studies and analyses. The conclusions are likely to be reliable.
This review investigated the effectiveness of red ginseng for treatment of erectile dysfunction. The authors concluded that the evidence was suggestive of effectiveness of red ginseng in treatment of erectile dysfunction, but the number and quality of trials were too low to draw firm conclusions. This study appeared to be generally well-conducted and the authors' cautious conclusions should be reliable.
This review assessed the efficacy and safety of trazodone for the treatment oferectile dysfunction. The authors' tentatively concluded that trazodone may be a helpful treatment for erectile dysfunction, particularly at higher doses and in men with psychogenic erectile dysfunction. The authors discussed some of the limitations of the review and rightly advised caution when interpreting the findings.
This review assessed the safety and efficacy of vardenafil, compared with placebo, for erectile dysfunction (ED). The authors concluded that vardenafil is superior to placebo in the treatment of symptoms of ED, although more research is required on its effectiveness and safety in different groups of patients. The authors' conclusions appear to be supported by the evidence presented, but the reliability of them is unclear.
This review of the efficacy of sildenafil, tadalafil and vardenafil for the treatment oferectile dysfunction concluded that all three drugs are highly effective; no differences were identified between them. The authors thoroughly investigated possible sources of bias in the review; their conclusions were in line with the evidence presented and likely to be reliable.
The authors concluded that patient characteristics such as baseline severity and duration of erectile dysfunction can significantly affect the findings of efficacy trials of sildenafil. Given the small number and size of the trials and limitations in the study methodology, the authors' findings are suggestive rather than definitive.
This meta-analytic study aims to estimate the likely improvements of erectile dysfunction (ED) measured by the International Index of Erectile Function (IIEF) at the highest fixed dosages of the three available PDE-5-inhibitors: sildenafil, tadalafil, and vardenafil. MEDLINE and the Cochrane Library were searched electronically for efficacy trials of PDE-5-inhibitors for treating ED. In addition drug manufacturers were contacted to provide unpublished or unrecorded congress proceedings. Randomized, double-blind, placebo-controlled, parallel-group, maximum fixed-dose, broad-spectrum efficacy trials using IIEF were included in the analysis. Data were independently extracted by two reviewers. The results were pooled using weighted mean differences. A formal indirect comparison (including Bonferroni-correction) was conducted to estimate the differences between agents. A total of 14 trials were included in the meta-analysis (three with 100 mg sildenafil, eight with 20-25 mg tadalafil, and three with 20 mg vardenafil). All trials were of good methodological quality. Overall heterogeneity was moderate: I(2)=33.2%, chi(2)=19.47, P=0.11. The funnel plot suggested moderate likelihood of publication bias. Pooled results of IIEF-improvement were for sildenafil 9.65 (95% CI: 8.50, 10.79) points, tadalafil 8.52 (7.61, 9.42) points, and vardenafil 7.50 (6.50, 8.50) points, respectively. Sildenafil proved to be significantly more effective than vardenafil (d=2.15, P=0.006), other pairwise comparisons showed no difference in efficacy. All PDE-5-inhibitors are highly effective in the treatment of ED. At maximum dosage they improve erectile function 7-10 points on the IIEF compared to placebo-treatment. There is evidence that sildenafil might be more efficacious than vardenafil, although this is to be interpreted with caution. To prove higher efficacy truly independent comparative trials are needed.
This review indirectly compared phosphodiesterase-5 (PDE-5) inhibitors for the treatment of erectile dysfunction. The authors concluded that common efficacy outcomes were similar between the PDE-5 inhibitors. Poor reporting of review methods, a limited search, and differences between the studies in terms of patient characteristics make it difficult to confirm the robustness of the conclusioN
OBJECTIVE: To review current evidence on the non-pharmacological (non-invasive) treatment of erectile dysfunction (ED).
OBJECTIVE: To compare suprapubic prostatectomy (SPPC) with transurethral resection of the prostate (TURP) in inducing erectile dysfunction (ED) and retrograde ejaculation (RE) in Chinese men.
OBJECTIVE: To evaluate the effectiveness of sildenafil versus continuous positive airway pressure (CPAP) for patients with erectile dysfunction (ED) and obstructive sleep apnea (OSA).
Thanks for sharing such a nice information from this blog. I found it so interesting at last i found now what i am looking for.Please continue the good work and I look forward to more of your nice posts in creating the new SharePoint group. Its great.buy Levitra
ReplyDeleteYour blog article is really very appreciable because if we providing some products which is related to pharmacy then there should also be the presence of simple online ordering system for the better knowledge of customers and for clearing their doubts.
ReplyDeleteSildenafil 20 mg | Vegalis 20 mg